Clinical Trial Update: Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating whether high-dose omega-3 fatty acids (Omacor) improve clinical outcomes and serum lipids after acute myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Infarction

Drugs mentioned

• Omacor (omega-3-acid ethyl esters)

Snippet

Sponsor: Helse Stavanger HF | Conditions: Coronary Disease, Myocardial Infarction | Phase 3 | Status: COMPLETED